ANI Plans To Shutter Oakville Plant By Q1 2023
Action Part Of Ongoing Efforts To Consolidate Manufacturing Network
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
You may also be interested in...
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.